Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Lower dose capecitabine demonstrated favorable therapeutic index
October 13th, 2005
Scientists discovered that lower dose capecitabine demonstrated a more favorable therapeutic index. According to a study from the United States, "Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer. Post-marketing use of capecitabine at the FDA-approved dose (2500 mg/m2/day) leads to unacceptable toxicity in many patients. Dose reductions anecdotally improve tolerability without compromising efficacy. This retrospective analysis was designed to verify these anecdotal reports." "We retrospectively reviewed the records of 141 consecutive patients with metastatic breast cancer identified from pharmacy...
Source: Women's Health Weekly (2005-10-13)
|
